Glucocorticoid-induced osteoporosis.

被引:7
作者
Boulos P. [1 ]
Ioannidis G. [1 ]
Adachi J.D. [1 ]
机构
[1] St. Joseph's Hospital, McMaster University, 501 - 25 Charlton Avenue E, Hamilton, L8N, Ontario
关键词
Bone Mineral Density; Osteoporosis; Bone Loss; Vertebral Fracture; Alendronate;
D O I
10.1007/s11926-996-0069-4
中图分类号
学科分类号
摘要
This article attempts to evaluate the results of several recently published clinical trials of drugs used in the treatment and prevention of glucocorticoid-induced osteoporosis. Despite our lack of understanding regarding the biological mechanisms that lead to glucocorticoid-induced bone loss, effective therapy has been developed. Bisphosphonates have demonstrated significant treatment benefits and should be considered the therapy of choice for both the treatment and prevention of glucocorticoid-induced osteoporosis.
引用
收藏
页码:53 / 61
页数:8
相关论文
共 140 条
[1]  
Cushing H(1932)The basophil adenomas of the pituitary body and their clinical manifestations Bull Johns Hopkins Hosp 50 137-195
[2]  
Adinoff A(1983)Steroid-induced fractures and bone loss in patients with asthma N Engl J Med 309 265-268
[3]  
Hollister JR(1983)Glucocorticoid-induced osteoporosis N Engl J Med 309 306-308
[4]  
Baylink DJ(1994)Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss Brit J Rheumatol 33 348-350
[5]  
Mulder H(1994)Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids Chest 105 1722-1727
[6]  
Struys A(1998)Corticosteroidinduced bone loss in men J Clin Endocrinol Metab 83 801-806
[7]  
Ip M(1998)Low incidence of osteoporosis in a two year follow-up of early community based patients with rheumatoid arthritis Scand J Rheumatol 27 188-193
[8]  
Lam K(1994)Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis—a population based study Ann Rheum Dis 53 18-23
[9]  
Yam L(1993)Effects of corticosteroids on bone turnover Respir Med 87 15-20
[10]  
Pearce G(1983)Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy Metab Clin Exper 32 151-156